Pembrolizumab (Keytruda) for primary triple negative breast cancer
I work in the Policy and Campaigns team at Breast Cancer Now.
New breast cancer treatment pembrolizumab (also known as Keytruda) is currently being assessed by the National Institute for Health and Care Excellence (NICE) to see if it can be made available on the NHS for certain patients with primary triple negative breast cancer. It is taken in combination with chemotherapy before surgery and then followed with pembrolizumab alone after surgery.
Have you received this treatment - perhaps through the clinical trial? If so, we want to hear your experience of the treatment to inform our response to NICE. Your views can be shared anonymously.